sulfasalazine has been researched along with Cronkhite-Canada Syndrome in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Cronkhite-Canada Syndrome: A nonfamilial polyposis syndrome that is characterized by the presence of diffuse gastrointestinal polyposis, DIARRHEA, and PROTEIN-LOSING ENTEROPATHY. It was first reported by Cronkhite and Canada in 1955.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueyama, H | 1 |
| Fu, KI | 1 |
| Ogura, K | 1 |
| Murata, S | 1 |
| Miyazaki, A | 1 |
1 other study available for sulfasalazine and Cronkhite-Canada Syndrome
| Article | Year |
|---|---|
Successful treatment for Cronkhite-Canada syndrome with endoscopic mucosal resection and salazosulfapyridine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Endoscopy, Gastrointestina | 2014 |